<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355886</url>
  </required_header>
  <id_info>
    <org_study_id>9274</org_study_id>
    <secondary_id>NCI-2015-00083</secondary_id>
    <secondary_id>9274</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02355886</nct_id>
  </id_info>
  <brief_title>Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy</brief_title>
  <official_title>Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II/III trial studies gabapentin in reducing the need for pain
      medication in patients with bladder cancer undergoing surgery to remove the bladder and
      nearby tissue and organs. Gabapentin may reduce the amount of pain medicine required after
      surgery, improve pain after surgery, and/or reduce the length of hospital stay after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess if perioperative gabapentin will decrease post-operative analgesic requirements
      within the first 48 hours after radical cystectomy (RC) in patients undergoing RC as measured
      morphine equivalents.

      SECONDARY OBJECTIVES:

      I. To assess patient self-assessment of postoperative pain on Numeric Pain Scale (NPS) at 24
      and 48 hours.

      II. To assess time to return of bowel function (ROBF).

      III. To assess length of stay (LOS) following RC.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive gabapentin orally (PO) thrice daily (TID) for 48 hours after surgery.

      ARM II: Patients receive placebo PO TID for 48 hours after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 22, 2015</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient total equivalent analgesic requirement (morphine equivalents)</measure>
    <time_frame>48 hours post-radical cystectomy</time_frame>
    <description>The two study groups will be compared using the t-test with p &lt; 0.05 considered statistically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay following radical cystectomy</measure>
    <time_frame>Up to 48 hours post-radical cystectomy</time_frame>
    <description>The two study groups will be compared using the t-test with p &lt; 0.05 considered statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient self-assessed pain on numerical pain scale</measure>
    <time_frame>Up to 48 hours post-radical cystectomy</time_frame>
    <description>The two study groups will be compared using the t-test with p &lt; 0.05 considered statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return of bowel function</measure>
    <time_frame>Up to 48 hours post-radical cystectomy</time_frame>
    <description>The two study groups will be compared using the t-test with p &lt; 0.05 considered statistically significant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Bladder Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (gabapentin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gabapentin PO TID for 48 hours after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO TID for 48 hours after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (gabapentin)</arm_group_label>
    <other_name>Gralise</other_name>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (gabapentin)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bladder cancer

          -  Anticipated radical cystectomy with ileal conduit or orthotopic neobladder

        Exclusion Criteria:

          -  Presence of spinal cord injury including any form of paraplegia or quadriplegia

          -  Allergy to gabapentin

          -  Active alcohol dependence, defined as 2 or more positive questions on the CAGE
             alcoholism questionnaire

          -  Illicit drug use (excluding recreational marijuana)

          -  Chronic kidney disease with glomerular filtration rate &lt; 30 ml/min

          -  Pregnancy: All female patients &lt; 55 years old (yo) will be administered a urine
             pregnancy test prior to enrollment

          -  Non-English speaking patients

          -  Chronic gabapentin, or the similar drug pregabalin, use

          -  Chronic narcotic use (daily or near daily use for &gt; 90 days)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Wright</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

